No matter whether patients had CAD or not, the simpler regimen was linked to less mortality and major bleeding at 6 months.

GI bleeding after percutaneous coronary intervention among patients on dual antiplatelet therapy remains risky in terms of ...

Dual antiplatelet therapy with clopidogrel and aspirin can benefit patients with mild ischemic stroke when initiated up to 72 hours after symptom onset.

Antiplatelet use can lead to improved cardiovascular ... risks while benefiting from the protective effects of antiplatelet ...

TCT 456: Influence of Venoarterial Extracorporeal Membrane Oxygenation Timing on Outcome in Patients With Infarct-Related Cardiogenic Shock: A Subanalysis From the ECLS-SHOCK Trial Receive the the ...

This unique dual formulation provides the potential benefit for smooth transition from short-term intravenous to long-term oral antiplatelet therapy. It has a plasma half-life of approximately 12 ...

Various clinical, demographic and genetic variables can influence responsiveness to antiplatelet therapy. In 2008, Geisler et al. 10 showed that residual platelet activity in patients with ...

or two types of antiplatelet medications can be used in dual antiplatelet therapy. DAPT includes aspirin plus another antiplatelet medication called a P2Y 12 inhibitor (such as clopidogrel, prasugrel ...

Ideally, when DESs are implanted, long-term treatment with dual antiplatelet therapy should be considered because of the risk of late stent thrombosis in patients with DM. The role of PCI with ...

Cardiovascular disease is the leading cause of death in patients with chronic kidney disease (CKD) warranting optimized management.

As dual antiplatelet therapy (DAPT) durations have progressively decreased after PCI, the need for safe and effective DES has become even more important. In this context, Supraflex Cruz provides ...